Evidence map›Paper›PMID 26300787›Full record

ArticleFrontiers in physiology2015

In adenosine A2B knockouts acute treatment with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver.

Maria Peleli, Michael Hezel, Christa Zollbrecht, A Erik G Persson, Jon O Lundberg, Eddie Weitzberg, Bertil B Fredholm, Mattias Carlström

Open access · goldAbstract read
In one paragraph

Article in Frontiers in physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Purinergic signaling in diabetes and metabolism.Biochemical pharmacology · 2021
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Article
  13. Pathological overproduction: the bad side of adenosine.British journal of pharmacology · 2017
    Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maria PeleliDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
Michael HezelDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
Christa ZollbrechtDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
A Erik G PerssonDepartment of Medical Cell Biology, Uppsala University Stockholm, Sweden.
Jon O LundbergDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
Eddie WeitzbergDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
Bertil B FredholmDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
Mattias CarlströmDepartment of Physiology and Pharmacology, Karolinska Institutet Stockholm, Sweden.
Karolinska Institutet · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAccumulating studies suggest that nitric oxide (NO) deficiency and oxidative stress are central pathological mechanisms in type 2 diabetes (T2D). Recent findings demonstrate therapeutic effects by boosting the nitrate-nitrite-NO pathway, which is an alternative pathway for NO formation. This study aimed at investigating the acute effects of inorganic nitrate on glucose and insulin signaling in adenosine A2B receptor knockout mice (A(-/-) 2B), a genetic mouse model of impaired metabolic regulation.

methodsAcute effects of nitrate treatment were investigated in aged wild-type (WT) and A(-/-) 2B mice. One hour after injection with nitrate (0.1 mmol/kg, i.p.) or placebo, metabolic regulation was evaluated by intraperitoneal glucose and insulin tolerance tests. NADPH oxidase-mediated superoxide production and AMPK phosphorylation were measured in livers obtained from non-treated or glucose-treated mice, with or without prior nitrate injection. Plasma was used to determine insulin resistance (HOMA-IR) and NO signaling.

resultsA(-/-) 2B displayed increased body weight, reduced glucose clearance, and attenuated overall insulin responses compared with age-matched WT mice. Nitrate treatment increased circulating levels of nitrate, nitrite and cGMP in the A(-/-) 2B, and improved glucose clearance. In WT mice, however, nitrate treatment did not influence glucose clearance. HOMA-IR increased following glucose injection in the A(-/-) 2B, but remained at basal levels in mice pretreated with nitrate. NADPH oxidase activity in livers from A(-/-) 2B, but not WT mice, was reduced by nitrate treatment. Livers from A(-/-) 2B displayed reduced AMPK phosphorylation compared with WT mice, and this was increased by nitrate treatment. Finally, injection with the anti-diabetic agent metformin induced similar therapeutic effects in the A(-/-) 2B as observed with nitrate.

conclusionThe A(-/-) 2B mouse is a genetic mouse model of metabolic syndrome. Acute treatment with nitrate improved the metabolic profile in it, at least partly via reduction in oxidative stress and improved AMPK signaling in the liver.

Indexed as

insulin resistancemetabolic syndromeNADPH oxidasenitric oxidenitriteobesitysuperoxidetype 2 diabetes

Identifiers

PMID26300787
PMCPMC4528163
OpenAlexW1847334100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.